Form 6-K PureTech Health plc For: Jan 31
- Wall St rises as bank fears fade, focus on inflation data
- Google accuses Microsoft of anti-competitive Cloud practices
- Alibaba's (BABA) logistics unit Cainiao pursuing IPO at over $20B valuation - Bloomberg
- Tesla urges Model 3 buyers to 'take delivery' before expected tax credit reduction
- Roku (ROKU) stock gains on plans to cut 200 jobs, 6% of workforce
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January, 2023
Commission File Number 001-39670
PURETECH HEALTH PLC
(Translation of registrants name into English)
6 Tide Street, Suite 400
Boston, Massachusetts 02210
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the Company) announced the commencement of a $50 million share repurchase program (the Program) of its ordinary shares of one pence each (Ordinary Shares). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (Jefferies) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Companys general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 15, 2022, Chapter 12 of the Financial Conduct Authoritys UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.
During the month ended January 31, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:
Average Price Paid
per Ordinary Share
|Highest Price Paid||Lowest Price Paid|
January 24, 2023
January 26, 2023
January 27, 2023
January 30, 2023
January 31, 2023
During the month ended January 31, 2023, the Company repurchased an aggregate of 42,994 Ordinary Shares. As of January 31, 2023, the Companys issued share capital was 289,468,159 shares, 10,638,341 of which were held in treasury, resulting in total voting rights in the Company of 278,829,818 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:
January 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4652834.html
January 26, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4655609.html
January 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4656979.html
January 30, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4658507.html
January 31, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4660262.html
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|PURETECH HEALTH PLC|
|Date: February 3, 2023||By:|| |
/s/ Daphne Zohar
|Title:||Chief Executive Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
- Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 30 March 2023
- CNL Strategic Capital Announces Year-End Operating Results for 2022
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!